Systematic Review of Respiratory Syncytial Virus Vaccine Efficacy
DOI:
https://doi.org/10.54097/hset.v45i.7387Keywords:
Respiratory syncytial virus, Vaccine, Efficacy, Systematic review.Abstract
As the development of the vaccine against respiratory syncytial virus (VRS) has been rapid recently with the innovation of all sorts of gene engineering tools, it is necessary to analyse the efficacy of all kinds of relevant vaccines comprehensively to accelerate the massive usage of them. In order to achieve it, a systematic analysis was needed along with selecting all kinds of articles published from 2018 to 2020 in various databases (Pubmed, EMBASE and Cochrane library) to get the target data. The procedure was carried out by two independent examiners and supervised by another examiner. Five articles were picked, for a total of 12,719 observed people aged less than 3 months to about 26. The results of the RBM meta-analysis were that the estimated vaccine efficacy was 62% (95% CI: 36% to 78%) with high heterogeneity (I2 = 87%). The subgroup analysis showed that multiple factors contributed to the heterogeneity of the research and indicated that it is better to focus on modifying the vaccine on both infants and adults to prevent the spread of RSV. All in all, compared with other commercial vaccines, the efficacy of the RSV vaccine still needs to be improved and more trials on the safety and immunogenicity have to be operated in the future.
Downloads
References
Huang Wenbo. Epidemiological study of common paramyxoviruses, including human respiratory syncytial virus, parainfluenza virus and parapneumovirus in Guangzhou [D]. Guangzhou Medical University, 2013.
Chen J, Zhang L, Wu S-L. Epidemiological features of common respiratory viruses in children during the new crown epidemic [J]. Clinical and educational aspects of general medicine, 2020, 18(9):3.
Shang Z, Tan S, Ma D. Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies, Int J Biol Sci. 2021 Sep 27; 17(14): 4073-. 4091
Gao Xiulan, Zhou Shaozhen, Xie Tianqi, et al. Infection of 5 types of respiratory viruses in children of different ages [J]. Laboratory Medicine and Clinics, 2018, 15(22):3.
Guo Weiwei, Yan Xiaotong, Feng Zhishan, et al. Epidemiological study of respiratory syncytial virus causing respiratory infections in children and preliminary analysis of immune function [J]. Chinese Journal of Microbiology and Immunology, 2020, 40(2):6.
Walsh EE, Falsey AR, Scott DA, Gurtman A, Zareba AM, Jansen KU, Gruber WC, Dormitzer PR, Swanson KA, Radley D, Gomme E, Cooper D, Schmoele-Thoma B. A randomized phase 1/2 study of the Respiratory Syncytial Virus Prefusion F vaccine. j Infect Dis. 2022 Apr 19;225(8):1357-1366.
Hua Xiaoxia. Challenges and opportunities for RSV vaccine development [J]. Advances in Microbiology Immunology, 2017, 45(4):6.
Li H, Ren H, Zhang Y, et al. Research progress of human respiratory syncytial virus vaccine [J]. Chinese Journal of Biological Products, 2022, 35(10):8.
Meissner HC, Kimberlin DW. RSV immunoprophylaxis: do the benefits match the costs? Pediatrics. 2013 Nov;132(5):915-8.
Wang Min, Xu Peiyang, Wang Xiaowan, Dai Tao. Analysis of the Cochrane EPOC system for evaluating original research evidence source databases and their search strategies [J]. Journal of Medical Informatics, 2008, 29(5):13-19.
Madhi SA, Polack FP, Piedra PA, Munoz FM, Trenholme AA, Simões EAF, Swamy GK, Agrawal S, Ahmed K, August A, Baqui AH, Calvert A, Chen J, Cho I, Cotton MF, Cutland CL, Englund JA, Fix A, Gonik B, Hammitt L, Heath PT, de Jesus JN, Jones CE, Khalil A, Kimberlin DW, Libster R. Llapur CJ, Lucero M, Pérez Marc G, Marshall HS, Masenya MS, Martinón-Torres F, Meece JK, Nolan TM, Osman A, Perrett KP, Plested JS, Richmond PC, Snape MD, Shakib JH, Shinde V, Stoney T, Thomas DN, Tita AT, Varner MW, Vatish M, Vrbicky K, Wen J, Zaman K, Zar HJ, Glenn GM, Fries LF; Prepared for the Study Group. Respiratory syncytial virus vaccination in pregnancy and effects on infants. n Engl J Med. 2020 Jul 30;383(5):426-439.
Simões EAF, Center KJ, Tita ATN, Swanson KA, Radley D, Houghton J, McGrory SB, Gomme E, Anderson M, Roberts JP, Scott DA, Jansen KU, Gruber WC, Dormitzer PR, Gurtman AC. Respiratory syncytial virus F-protein immunization in pregnancy. n Engl J Med. 2022 Apr 28;386(17):1615-1626.
Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group. nirsevimab for the prevention of RSV in healthy late preterm and term infants. n Engl J Med. 2022 Mar 3;386(9):837-846.
Schmoele-Thoma B, Zareba AM, Jiang Q, Maddur MS, Danaf R, Mann A, Eze K, Fok-Seang J, Kabir G, Catchpole A, Scott DA, Gurtman AC, Jansen KU, Gruber WC, Dormitzer PR, Swanson KA. Vaccine efficacy in adults in the respiratory syncytial virus challenge study. n Engl J Med. 2022 Jun 23;386(25):2377-2386.
Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EAF, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP; Nirsevimab Research. Group. Single-dose nirsevimab for prevention of RSV in preterm infants. n Engl J Med. 2020 Jul 30;383(5):415-425. erratum in: N Engl J Med. 2020 Aug 13;383(7):698.
Qi Yi, Yang Yechun, Kong Zongmei. Analysis of the trend and influencing factors of hospitalization rate in Guangdong Province [J]. Modern Hospital, 2022(022-004).
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
